{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:49Z","timestamp":1786116589579,"version":"build-2736575974"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers with a relative 5-year survival around 12%. One of the greatest challenges in PDAC is the frequent systemic dissemination at the time of diagnosis and the dense, fibrotic extracellular matrix that prevents chemotherapeutics and cytotoxic immune cells from entering the tumor stroma. The cyclooxygenase (COX) enzymes and their downstream molecular products play important roles in cancer development and dissemination. The COX isoenzymes are overexpressed in many cancers and inhibition of the COX-2 isoform, and the use of acetylsalicylic acid has recently been demonstrated to reduce cancer recurrence after surgery in subgroups of patients with certain molecular subtypes, such as PI3K mutations, overexpression of vascular growth factors, etc.). COX-2-related pathways are involved in suppressing tumor immunity and promoting stem cell-like properties of cancer cells. Especially in PDAC, targeting the COX enzymes might be of importance in subgroups or as an adjunct as COX-2 is frequently overexpressed and associated with a worse prognosis. Selective COX-2 inhibitors have been demonstrated to reduce tumor growth, invasiveness, and metastasis formation in preclinical trials. This review evaluates existing preclinical and clinical studies investigating the potential for targeting the COX enzymes in PDAC treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1916208","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:57:30Z","timestamp":1786013850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclooxygenases in pancreatic ductal adenocarcinoma: are they inflammatory catalysts for tumor growth"],"prefix":"10.3389","volume":"16","author":[{"given":"Adile","family":"Orhan","sequence":"first","affiliation":[{"name":"Center for Surgical Science, Department of Surgery, Zealand University Hospital","place":["Koege, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Orhan","sequence":"additional","affiliation":[{"name":"Center for Surgical Science, Department of Surgery, Zealand University Hospital","place":["Koege, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Raskov","sequence":"additional","affiliation":[{"name":"Center for Surgical Science, Department of Surgery, Zealand University Hospital","place":["Koege, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"G\u00f6genur","sequence":"additional","affiliation":[{"name":"Center for Surgical Science, Department of Surgery, Zealand University Hospital","place":["Koege, Denmark"]},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801238-3.65801-4","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nat 2008 454:7203"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat Rev Immunol 2015 15:8"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14912","article-title":"Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts","volume":"8","author":"Krishnamachary","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(01)01255-9","article-title":"The role of cyclooxygenase-2 in prostate cancer","volume":"58","author":"Kirschenbaum","year":"2001","journal-title":"Urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2003.09.006","article-title":"Overexpression of cyclooxygenase-2 in non-small cell lung cancer","volume":"98","author":"Petkova","year":"2004","journal-title":"Respir Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.10.4711","article-title":"Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer","volume":"6","author":"Matsubayashi","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/b0-12-443710-9\/00478-6","article-title":"Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention","volume":"111","author":"Dennis","year":"2011","journal-title":"Chem Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021353","article-title":"The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles","volume":"24","author":"Khan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.557280","article-title":"Interplay between EGFR and the platelet-activating factor\/PAF receptor signaling axis mediates aggressive behavior of cervical cancer","volume":"10","author":"Souza","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00447","article-title":"TNF-\u03b1-induced cPLA2 expression via NADPH oxidase\/reactive oxygen species-dependent NF-\u03baB cascade on human pulmonary alveolar epithelial cells","volume":"7","author":"Lin","year":"2016","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/S12974-015-0419-0","article-title":"Cytosolic phospholipase A2 plays a crucial role in ROS\/NO signaling during microglial activation through the lipoxygenase pathway","volume":"12","author":"Chuang","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B16","article-title":"COX-1 and COX-2 tissue expression: implications and predictions","volume":"49","author":"Crofford","year":"1997","journal-title":"J Rheumatol Suppl"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1607","article-title":"Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer","volume":"84","author":"Leung","year":"2001","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.41.29138","article-title":"Regulation of cyclooxygenase-2 by interferon \u03b3 and transforming growth factor \u03b1 in normal human epidermal keratinocytes and squamous carcinoma cells: role of mitogen-activated protein kinases","volume":"274","author":"Matsuura","year":"1999","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.07.006","article-title":"Differential COX-2 induction by viral and bacterial PAMPs: consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies","volume":"438","author":"Kirkby","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.9939","article-title":"Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells","volume":"254","author":"Inoue","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-3-8","article-title":"Non-steroid anti-inflammatory drugs, prostaglandins, and cancer","volume":"3","author":"Allaj","year":"2013","journal-title":"Cell Bioscience 2013 3:1"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-83438-z","article-title":"Three-dimensional structure of human cyclooxygenase (hCOX)-1","volume":"11","author":"Miciaccia","year":"2021","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.222543099","article-title":"Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum","volume":"99","author":"Warner","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2014-1252","article-title":"6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3860","article-title":"Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer","volume":"6","author":"Wilson","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.53347\/rid-22630","article-title":"Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma","volume":"8","author":"Osman","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.141.7.1515","article-title":"The mammalian calcium-binding protein, nucleobindin (CALNUC), is a Golgi resident protein","volume":"141","author":"Lin","year":"1998","journal-title":"J Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.11.5544","article-title":"Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein","volume":"93","author":"Ballif","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6785","article-title":"Downregulation of cyclooxygenase-1 stimulates mitochondrial apoptosis through the NF-\u03baB signaling pathway in colorectal cancer cells","volume":"41","author":"Ding","year":"2019","journal-title":"Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3998\/ark.5550190.0007.810","article-title":"PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation","volume":"80","author":"Perrone","year":"2014","journal-title":"Eur J Med Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J Cell Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-29606-9","article-title":"Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations","volume":"13","author":"Bell","year":"2022","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/bf02554806","article-title":"Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study","volume":"48","author":"Kune","year":"1988","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199112053252301","article-title":"Aspirin use and reduced risk of fatal colon cancer","volume":"325","author":"Thun","year":"1991","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.prostaglandins.2005.01.002","article-title":"COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice","volume":"76","author":"Narko","year":"2005","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8553(05)70252-1","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81988-1","article-title":"Suppression of intestinal polyposis in Apc\u0394716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)","volume":"87","author":"Oshima","year":"1996","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/jci73530","article-title":"Prostanoid induces premetastatic niche in regional lymph nodes","volume":"124","author":"Ogawa","year":"2014","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1541-7786.mcr-09-0336","article-title":"Cyclooxygenase-deficient pancreatic cancer cells utilize exogenous sources of prostaglandins","volume":"8","author":"Omura","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.05.023","article-title":"Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway","volume":"62","author":"Maeng","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.2.657","article-title":"Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells","volume":"94","author":"Coffey","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-0453","article-title":"Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer","volume":"18","author":"Kirane","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25473","article-title":"Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer","volume":"117","author":"Reckamp","year":"2011","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs195","article-title":"Epithelial\u2013mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib","volume":"33","author":"Kirane","year":"2012","journal-title":"Carcinogenesis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m411221200","article-title":"15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer","volume":"280","author":"Backlund","year":"2005","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902367106","article-title":"15-hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors","volume":"106","author":"Yan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.accreview.2005.05.024","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nature05760","article-title":"Mediators of vascular remodelling co-opted for sequential steps in lung metastasis","volume":"446","author":"Gupta","year":"2007","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-12-0342","article-title":"Cell intrinsic role of COX-2 in pancreatic cancer development","volume":"11","author":"Hill","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0b013e31815878c9","article-title":"Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: Results of a phase II trial","volume":"31","author":"Dragovich","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-1028-z","article-title":"A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer","volume":"23","author":"El-Rayes","year":"2005","journal-title":"Invest New Drugs"},{"key":"B56","article-title":"Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer","volume":"59","author":"Tucker","year":"1999","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02829.x","article-title":"Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer","volume":"17","author":"Kong","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.2.139","article-title":"Cyclooxygenase-2 expression in human pancreatic adenocarcinomas","volume":"21","author":"Yip-Schneider","year":"2000","journal-title":"Carcinogenesis"},{"key":"B59","article-title":"Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs","volume":"59","author":"Molina","year":"1999","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/bf02781733","article-title":"Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors","volume":"26","author":"Koshiba","year":"1999","journal-title":"Int J Pancreatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-0677","article-title":"Gene expression profiling of tumor\u2013stromal interactions between pancreatic cancer cells and stromal fibroblasts","volume":"64","author":"Sato","year":"2004","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.6.455","article-title":"Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer","volume":"90","author":"Hwang","year":"1998","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04700","article-title":"Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia","volume":"8","author":"Crowell","year":"2006","journal-title":"Neoplasia"},{"key":"B64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/1-4020-5688-5_9","article-title":"Cancer chemoprevention by cyclooxygenase 2 blockade: Results of case control studies","volume":"42","author":"Harris","year":"2007","journal-title":"Sub-cell Biochem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/s0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32820","article-title":"Premetastatic niches, exosomes and circulating tumor cells: Early mechanisms of tumor dissemination and the relation to surgery","volume":"146","author":"Raskov","year":"2020","journal-title":"Int J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: Organ-specific homes for metastases","volume":"17","author":"Psaila","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090607","article-title":"COX-2 and prostaglandin EP3\/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems","volume":"176","author":"Katoh","year":"2010","journal-title":"Am J Pathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468264","article-title":"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2\u2013dependent prostaglandin E2 in human dendritic cells","volume":"122","author":"Trinath","year":"2013","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J"},{"key":"B71","doi-asserted-by":"crossref","first-page":"214269","DOI":"10.1155\/2011\/214269","article-title":"Involvement of COX-2\/PGE(2) pathway in the upregulation of MMP-9 expression in pancreatic cancer","volume":"2011","author":"Bu","year":"2011","journal-title":"Gastroenterol Res Pract"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2016.06.251","article-title":"Hyaluronan stimulates pancreatic cancer cell motility","volume":"7","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8219","article-title":"Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m703811200","article-title":"Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells","volume":"283","author":"Misra","year":"2008","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.biopha.2017.12.111","article-title":"Anti\u2010inflammatory and anti\u2010tumor effects of \u03b1-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model","volume":"98","author":"Hosseini","year":"2018","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8786","article-title":"Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E(2)","volume":"16","author":"Xie","year":"2018","journal-title":"Oncol Lett"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1064-9","article-title":"Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4","volume":"60","author":"Holt","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B79","article-title":"Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages","volume":"60","author":"Dubey","year":"2014","journal-title":"Cell Mol Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m002329200","article-title":"Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways","volume":"275","author":"Paik","year":"2000","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor\u2013based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00387","article-title":"The role of myeloid-derived suppressor cells in immune ontogeny","volume":"5","author":"Gantt","year":"2014","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3109\/08820139.2012.673191","article-title":"Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship","volume":"41","author":"Monu","year":"2012","journal-title":"Immunol Invest"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function","volume":"10","author":"Veltman","year":"2010","journal-title":"BMC Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prostaglandins.2014.10.003","article-title":"Prostaglandin E2 switches from a stimulator to an inhibitor of cell migration after epithelial-to-mesenchymal transition","author":"Li","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03332-5","article-title":"Immunological combination treatment holds the key to improving survival in pancreatic cancer","volume":"146","author":"Sodergren","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1172\/jci127755","article-title":"Tumor cell\u2013intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)","volume":"129","author":"Markosyan","year":"2019","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now049","article-title":"Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma","volume":"18","author":"Cook","year":"2016","journal-title":"Neuro Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2014.09.012","article-title":"ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury","volume":"3","author":"Zhang","year":"2014","journal-title":"Stem Cell Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05607","article-title":"Aberrant Wnt\/beta-catenin signaling in pancreatic adenocarcinoma","volume":"8","author":"Zeng","year":"2006","journal-title":"Neoplasia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(02)01014-0","article-title":"The \u03b2-catenin\/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells","volume":"111","author":"van de Wetering","year":"2002","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2048","article-title":"Wnt activity defines colon cancer stem cells and is regulated by the microenvironment","volume":"12","author":"Vermeulen","year":"2010","journal-title":"Nat Cell Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19283","article-title":"Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.015","article-title":"Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration","volume":"136","author":"Goessling","year":"2009","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018562","article-title":"Wnt\/\u03b2-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells","volume":"6","author":"Nu\u00f1ez","year":"2011","journal-title":"PloS One"},{"key":"B100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2008.10.053","article-title":"Suppression of Wnt\/beta-catenin signaling inhibits prostate cancer cell proliferation","volume":"602","author":"Lu","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9050","article-title":"Wnt2 contributes to the progression of gastric cancer by promoting cell migration and invasion","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.241638","article-title":"Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt\/\u03b2-catenin signalling pathway","volume":"60","author":"Fu","year":"2011","journal-title":"Gut"},{"key":"B103","article-title":"Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer","volume":"4","author":"Jiang","year":"2014","journal-title":"Am J Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/S41389-022-00398-3","article-title":"Neutrophils and polymorphonuclear myeloid-derived suppressor cells: An emerging battleground in cancer therapy","volume":"11","author":"Raskov","year":"2022","journal-title":"Oncogenesis"},{"key":"B106","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/j.0818-9641.2004.01251.x","article-title":"Prostanoids and their receptors that modulate dendritic cell-mediated immunity","volume":"82","author":"Gualde","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.531","article-title":"Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity","volume":"5","author":"G\u00f6bel","year":"2014","journal-title":"Cell Death Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.05.002","article-title":"PGE2 inhibits natural killer and \u03b3\u03b4 T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling","volume":"80","author":"Martinet","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"B110","article-title":"Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression","volume":"3","author":"Elder","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0299fje","article-title":"COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib","volume":"15","author":"Groesch","year":"2001","journal-title":"FASEB J"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.4.451","article-title":"Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts","volume":"190","author":"Zhang","year":"1999","journal-title":"J Exp Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(99)00200-2","article-title":"Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines","volume":"58","author":"Lim","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-5347(05)65856-9","article-title":"Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy","volume":"166","author":"Goluboff","year":"2001","journal-title":"J Urol"},{"key":"B115","article-title":"Exisulind induction of apoptosis involves guanosine 3\u2019,5\u2019-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin","volume":"60","author":"Thompson","year":"2000","journal-title":"Cancer Res"},{"key":"B116","article-title":"Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1","volume":"6","author":"Soh","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I\u03baB kinase-\u03b2","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5493.989","article-title":"Role of BAX in the apoptotic response to anticancer agents","volume":"290","author":"Zhang","year":"2000","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81664-5","article-title":"PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs","volume":"99","author":"He","year":"1999","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.051630998","article-title":"Genetic disruption of PPAR\u03b4 decreases the tumorigenicity of human colon cancer cells","volume":"98","author":"Park","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0705505104","article-title":"Transcriptional network governing the angiogenic switch in human pancreatic cancer","volume":"104","author":"Abdollahi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1172\/jci9621","article-title":"Host cyclooxygenase-2 modulates carcinoma growth","volume":"105","author":"Williams","year":"2000","journal-title":"J Clin Invest"},{"key":"B123","first-page":"6045","article-title":"Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models","volume":"60","author":"Williams","year":"2000","journal-title":"Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(95)00956-a","article-title":"Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin\u20101: a potential mechanism for inflammatory angiogenesis","volume":"372","author":"Ben - Av","year":"1995","journal-title":"FEBS Lett"},{"key":"B125","article-title":"Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer","volume":"58","author":"Bouvet","year":"1998","journal-title":"Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.16.10911","article-title":"Inhibition of cyclooxygenase-2 gene expression by p53","volume":"274","author":"Subbaramaiah","year":"1999","journal-title":"J Biol Chem"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell Press"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075102","article-title":"The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2","volume":"8","author":"Peulen","year":"2013","journal-title":"PloS One"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s148670","article-title":"Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis","volume":"11","author":"Dai","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2174\/0929867325666180307112029","article-title":"Mitochondria-targeting anticancer metal complexes","volume":"26","author":"Erxleben","year":"2019","journal-title":"Curr Med Chem"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.214316","article-title":"Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX\u20131 and COX\u20132 enzymes","volume":"453","author":"Yasir Khan","year":"2022","journal-title":"Coord Chem Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2504650","article-title":"Low-dose aspirin for PI3K-altered localized colorectal cancer","volume":"393","author":"Martling","year":"2025","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051679","article-title":"Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors","volume":"174","author":"L\u00e9vesque","year":"2006","journal-title":"CMAJ"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00113","article-title":"The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults","volume":"142","author":"L\u00e9vesque","year":"2005","journal-title":"Ann Intern Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.05.008","article-title":"The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs","volume":"38","author":"Grosser","year":"2017","journal-title":"Trends Pharmacol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:57:33Z","timestamp":1786013853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":136,"alternative-id":["10.3389\/fonc.2026.1916208"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1916208","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1916208"}}